M&A activity among pharmaceutical outsourcing companies in 2006 was rapid. In this highly fragmented industry, consolidation often marked companies’ interest in establishing an international reach. Covalent Group’s acquisition of Remedium Oy is an example of this. Another trend was a shift among private equity firms towards expanding their portfolio outsourcing companies with an eye on […]

According to a survey by Chemical & Engineering News, the 16 chemical firms that gave answers about capital spending will increase capital spending by an average of 7.6% this year. Increases of 28.1% and 16.5% were recorded in 2005 and 2006, respectively. Among the firms, the largest increase in capital investments, 36.4%, will be recorded […]

According to a report by the Statistics Bureau of Japan’s Ministry of Internal Affairs and Communications, total R&D expenditures for Japanese fiscal year (JFY) 2005 (April 1, 2005-March 31, 2006) were ¥17,845.2 billion ($156.5 billion), up 5.4% from JFY 2004. Of this, natural sciences R&D made up ¥16,472.1 billion ($144.5 billion). R&D was 3.53% of […]

Earlier this month, the FDA gave its recommendations to Congress for the next reauthorization of the Prescription Drug User Fee program. In order to support these changes, the FDA recommends that the annual user fee collections be increased $87.4 million to $392.8 million. The Prescription Drug User Fee Act (PDUFA) of November 1992 first authorized […]